INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 155 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $5,179,000 | +2.7% | 42,775 | -4.0% | 0.70% | +4.0% |
| Q1 2017 | $5,041,000 | +3.1% | 44,573 | -1.0% | 0.67% | +2.6% |
| Q4 2016 | $4,890,000 | +1788.0% | 45,005 | +4090.4% | 0.66% | +644.3% |
| Q2 2015 | $259,000 | -14.5% | 1,074 | 0.0% | 0.09% | -62.6% |
| Q1 2015 | $303,000 | – | 1,074 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |